25.89
+1.31(+5.33%)
Currency In USD
| Previous Close | 24.58 |
| Open | 24.58 |
| Day High | 25.95 |
| Day Low | 24.27 |
| 52-Week High | 28.25 |
| 52-Week Low | 5.9 |
| Volume | 2.76M |
| Average Volume | 5.67M |
| Market Cap | 2.78B |
| PE | -5.52 |
| EPS | -4.69 |
| Moving Average 50 Days | 16.52 |
| Moving Average 200 Days | 11.35 |
| Change | 1.31 |
If you invested $1000 in Intellia Therapeutics, Inc. (NTLA) since IPO date, it would be worth $1,171.49 as of October 24, 2025 at a share price of $25.89. Whereas If you bought $1000 worth of Intellia Therapeutics, Inc. (NTLA) shares 5 years ago, it would be worth $1,056.73 as of October 24, 2025 at a share price of $25.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 03, 2025 8:01 PM GMT
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, i
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
GlobeNewswire Inc.
Sep 25, 2025 1:52 PM GMT
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observ
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
GlobeNewswire Inc.
Sep 22, 2025 11:30 AM GMT
Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measuresCAMBRIDGE, M